[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Indexing Sources::
Editorial Board::
Executive Members::
Articles Archive::
Instruction to Authors::
Peer-Review::
Contact Us::
Site Facilities::
::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.

Happy Persian New Year (Nowruz)


:: Volume 23, Issue 4 (12-2021) ::
J Gorgan Univ Med Sci 2021, 23(4): 33-39 Back to browse issues page
Can use NKX2-1 Gene as Indicator of Differentiation of Papillary Thyroid Carcinoma?
Mohammad Mokhtari1 , Seyed-Morteza Javadirad 2, Mohsen Kolahdouzan3
1- M.Sc Student of Cellular and Molecular Biology, Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran.
2- Assistant Professor, Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran. , javadirad@yahoo.com
3- Associate Professor, Department of Surgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Abstract:   (4764 Views)
Background and Objective: Thyroid cancer is a common cancer of the endocrine system, and knowing the etiology can be effective in its treating. On the other hand, the FNA technique is not accurate enough, so finding a biomarker for thyroid cancer is of importance. This study was done to evaluate the NKX2-1 gene as indicator of differentiation of papillary thyroid carcinoma (PTC).
Methods: In this case-control study, 17 fresh PTC tissue samples and 20 adjacent-healthy tissues were collected during thyroidectomy in Isfahan, Iran. RNA extraction was followed by cDNA synthesis. The expression of the NKX2-1 gene was performed using specific primers (exon-junction and intron spanning) using the RT-qPCR method.
Results: An examination of the quality and quantity of extracted RNAs showed that they were intact and suitable for making cDNA. Examination of the melting curve showed a specific amplification of the NKX2-1 gene. The difference in expression of the NKX2-1 gene between PTC and healthy-adjacent tissues was 0.947.
Conclusion: No difference in the expression of the NKX2-1 gene between the healthy tissue adjacent to the tumor and the tissue of the PTC tumor indicates that the PTC tumors were differentiated.
Keywords: Papillary Thyroid Cancer [MeSH], Cell Differentiation [MeSH], NKX2-1 [MeSH]
Article ID: Vol23-51
Full-Text [PDF 799 kb]   (15223 Downloads)    
Type of Study: Original Articles | Subject: Molecular Medicine
References
1. Safavi A, Azizi F, Jafari R, Chaibakhsh S, Safavi AA. Thyroid Cancer Epidemiology in Iran: a Time Trend Study. Asian Pac J Cancer Prev. 2016; 17(1): 407-12. DOI: 10.7314/apjcp.2016.17.1.407 [DOI] [PubMed]
2. Shah JP. Thyroid carcinoma: epidemiology, histology, and diagnosis. Clin Adv Hematol Oncol. 2015 Apr; 13(4 Suppl 4): 3-6. [View at Publisher]
3. Hughes DT, Haymart MR, Miller BS, Gauger PG, Doherty GM. The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid. 2011 Mar; 21(3): 231-36. DOI: 10.1089/thy.2010.0137 [DOI] [PubMed]
4. Reiners C, Wegscheider K, Schicha H, Theissen P, Vaupel R, Wrbitzky R, et al. Prevalence of thyroid disorders in the working population of Germany: ultrasonography screening in 96,278 unselected employees. Thyroid. 2004 Nov; 14(11): 926-32. DOI: 10.1089/thy.2004.14.926 [DOI] [PubMed]
5. DeLellis RA, Lloyd RV, Heitz PU, Eng C. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. International Agency for Research on Cancer. 2004.
6. Lloyd RV, Buehler D, Khanafshar E. Papillary thyroid carcinoma variants. Head Neck Pathol. 2011 Mar; 5(1): 51-56. DOI: 10.1007/s12105-010-0236-9 [DOI] [PubMed]
7. Memon A, Rogers I, Paudyal P, Sundin J. Dental X-Rays and the Risk of Thyroid Cancer and Meningioma: A Systematic Review and Meta-Analysis of Current Epidemiological Evidence. Thyroid. 2019 Nov; 29(11): 1572-93. DOI: 10.1089/thy.2019.0105 [DOI] [PubMed]
8. Memon A, Godward S, Williams D, Siddique I, Al-Saleh K. Dental x-rays and the risk of thyroid cancer: a case-control study. Acta Oncol. 2010 May; 49(4): 447-53. DOI: 10.3109/02841861003705778 [DOI] [PubMed]
9. diMarco A, Palazzo F. Goitre and thyroid cancer. Medicine. 2017; 45(8): 517-22. DOI: 10.1016/j.mpmed.2017.05.004 [View at Publisher] [DOI]
10. Kim SJ, Lee KE, Myong JP, Park JH, Jeon YK, Min HS, et al. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg. 2012 Feb; 36(2): 310-17. DOI: 10.1007/s00268-011-1383-1 [DOI] [PubMed]
11. Leeman-Neill RJ, Brenner AV, Little MP, Bogdanova TI, Hatch M, Zurnadzy LY, et al. RET/PTC and PAX8/PPARγ chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics. Cancer. 2013 May; 119(10): 1792-99. DOI: 10.1002/cncr.27893 [DOI] [PubMed]
12. Szymańska K, Bosman FT. Thyroid Cancer. Pathology and Genetics, Diagnosis and Treatment. In: Boffetta P, Hainaut P. Encyclopedia of Cancer. 3rd ed. Oxford: Academic Press. 2018; pp: 471-82.
13. Zhang P, Zuo H, Nakamura Y, Nakamura M, Wakasa T, Kakudo K. Immunohistochemical analysis of thyroid-specific transcription factors in thyroid tumors. Pathol Int. 2006 May; 56(5): 240-45. DOI: 10.1111/j.1440-1827.2006.01959.x [DOI] [PubMed]
14. Lambert M, Jambon S, Depauw S, David-Cordonnier MH. Targeting Transcription Factors for Cancer Treatment. Molecules. 2018 Jun; 23(6): 1479. DOI: 10.3390/molecules23061479 [DOI] [PubMed]
15. Hall TL, Layfield LJ, Philippe A, Rosenthal DL. Sources of diagnostic error in fine needle aspiration of the thyroid. Cancer. 1989 Feb; 63(4): 718-25. DOI: 10.1002/1097-0142(19890215)63:4<718::aid-cncr2820630420>3.0.co;2-n [DOI] [PubMed]
16. Nikiforova MN, Nikiforov YE. Molecular diagnostics and predictors in thyroid cancer. Thyroid. 2009 Dec; 19(12): 1351-61. DOI: 10.1089/thy.2009.0240 [DOI] [PubMed]
17. Adamski MG, Gumann P, Baird AE. A method for quantitative analysis of standard and high-throughput qPCR expression data based on input sample quantity. PLoS One. 2014 Aug; 9(8): e103917. DOI: 10.1371/journal.pone.0103917 [DOI] [PubMed]
18. Randazzo W, Vasquez-García A, Aznar R, Sánchez G. Viability RT-qPCR to Distinguish Between HEV and HAV With Intact and Altered Capsids. Front Microbiol. 2018 Aug; 9: 1973. DOI: 10.3389/fmicb.2018.01973 [DOI] [PubMed]
19. Prasad NB, Kowalski J, Tsai HL, Talbot K, Somervell K, Kouniavsky G, et al. Three-gene molecular diagnostic model for thyroid cancer. Thyroid. 2012 Mar; 22(3): 275-84. DOI: 10.1089/thy.2011.0169 [DOI] [PubMed]
20. Onda M, Emi M, Yoshida A, Miyamoto S, Akaishi J, Asaka S, et al. Comprehensive gene expression profiling of anaplastic thyroid cancers with cDNA microarray of 25 344 genes. Endocr Relat Cancer. 2004 Dec; 11(4): 843-54. DOI: 10.1677/erc.1.00818 [DOI] [PubMed]
21. Lazzaro D, Price M, de Felice M, Di Lauro R. The transcription factor TTF-1 is expressed at the onset of thyroid and lung morphogenesis and in restricted regions of the foetal brain. Development. 1991 Dec; 113(4): 1093-104. [PubMed]
22. De Felice M, Di Lauro R. Thyroid development and its disorders: genetics and molecular mechanisms. Endocr Rev. 2004 Oct; 25(5): 722-46. DOI: 10.1210/er.2003-0028 [DOI] [PubMed]
23. Civitareale D, Lonigro R, Sinclair AJ, Di Lauro R. A thyroid-specific nuclear protein essential for tissue-specific expression of the thyroglobulin promoter. EMBO J. 1989 Sep; 8(9): 2537-42. [PubMed]
24. Francis-Lang H, Price M, Polycarpou-Schwarz M, Di Lauro R. Cell-type-specific expression of the rat thyroperoxidase promoter indicates common mechanisms for thyroid-specific gene expression. Mol Cell Biol. 1992 Feb; 12(2): 576-88. DOI: 10.1128/mcb.12.2.576-588.1992 [DOI] [PubMed]
25. Civitareale D, Castelli MP, Falasca P, Saiardi A. Thyroid transcription factor 1 activates the promoter of the thyrotropin receptor gene. Mol Endocrinol. 1993 Dec; 7(12): 1589-95. DOI: 10.1210/mend.7.12.8145764 [DOI] [PubMed]
26. Kimura S. Thyroid-specific enhancer-binding protein: Role in thyroid function and organogenesis. Trends in Endocrinology and Metabolism. 1996; 7(7): 247-52. DOI: 10.1016/S1043-2760(96)00115-4 [Article] [DOI]
27. Alotaibi H, Tuzlakoğlu-Öztürk M, Tazebay UH. The Thyroid Na+/I- Symporter: Molecular Characterization and Genomic Regulation. Mol Imaging Radionucl Ther. 2017 Feb; 26(Suppl 1): 92–101. DOI: 10.4274/2017.26.suppl.11 [DOI] [PubMed]
28. Fabbro D, Di Loreto C, Beltrami CA, Belfiore A, Di Lauro R, Damante G. Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res. 1994 Sep; 54(17): 4744-49. [PubMed]
29. Sethi K, Sarkar S, Das S, Mohanty B, Mandal M. Biomarkers for the diagnosis of thyroid cancer. J Exp Ther Oncol. 2010; 8(4): 341-52. [PubMed]
30. Kondo T, Nakazawa T, Ma D, Niu D, Mochizuki K, Kawasaki T, et al. Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas. Lab Invest. 2009 Jul; 89(7): 791-99. DOI: 10.1038/labinvest.2009.50 [DOI] [PubMed]
Send email to the article author


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mokhtari M, Javadirad S, Kolahdouzan M. Can use NKX2-1 Gene as Indicator of Differentiation of Papillary Thyroid Carcinoma?. J Gorgan Univ Med Sci 2021; 23 (4) :33-39
URL: http://goums.ac.ir/journal/article-1-3875-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 23, Issue 4 (12-2021) Back to browse issues page
مجله دانشگاه علوم پزشکی گرگان Journal of Gorgan University of Medical Sciences
Persian site map - English site map - Created in 0.06 seconds with 38 queries by YEKTAWEB 4645